During the third quarter, Asset Management One Co. Ltd. boosted its holdings in Medtronic by 2.4%, adding 13,594 shares to reach a total of 589,186 shares. At the end of the period, the fund’s stake in the medical technology company was valued at $56.11 million, marking a meaningful uptick in exposure to the firm’s diversified device portfolio.

Several other institutional investors also adjusted their Medtronic positions in the same quarter. Gateway Investment Advisers LLC lifted its stake by 1.6% to 90,237 shares (worth $8.59 million), DMKC Advisory Services LLC added 0.9% for a total of 24,230 shares ($2.31 million), Moss Adams Wealth Advisors LLC increased by 3.4% to 4,431 shares ($425,000), Saxony Capital Management LLC rose 3.8% to 3,046 shares ($290,000), and Global Retirement Partners LLC expanded by 17.1% to 33,584 shares ($3.20 million). Overall, institutional investors now control just over 82% of the company’s shares.

Medtronic’s market capitalization stands at $123.11 billion, supported by a price-to-earnings ratio of 25.88 and a price-to-earnings-growth ratio of 2.53. The company exhibits a beta of 0.71, a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80, reflecting solid liquidity and conservative leverage in light of its global product mix spanning cardiac, surgical and diabetes care technologies.

In its latest quarter, Medtronic reported earnings per share of $1.36, beating consensus by $0.05, on revenue of $8.96 billion, up 6.6% year-over-year and $100 million above estimates. Return on equity reached 14.86% with a net margin of 13.71%. Management set full-year EPS guidance at a range of 5.620 to 5.660, compared with the Street’s view of 5.46. The board declared a quarterly dividend of $0.71 per share, translating to a 3.0% yield and a 76.55% payout ratio, payable January 16 with a record date of December 26.